Cannabis Law Report

APRIL 19, 2023

Here’s the blurb With research showing that psychedelics hold substantial promise for the treatment of mental health conditions such as depression, PTSD and addiction, PSYCH Symposium provides a platform for decision makers to accelerate the development and delivery of these medicines.

Research and Development 52

Research and Development Events Treatment Policy 52

Project CBD

NOVEMBER 11, 2023

NM: As someone who has been researching cannabis for decades, how do you feel about the current legalization situation worldwide and in Japan, in particular? Dr. Andrew Weil: I think the trend very clearly is that in most developed countries, cannabis is being made legal first for medical uses and then also for recreational uses.

Medicine 301

Medicine Research and Development Pharmaceutical Cannabis 301

MMJ Recs

FEBRUARY 10, 2024

Scientific research, patient testimonials, and a broader understanding of the plant’s medicinal properties have fundamentally altered public views. This change is driven by a combination of scientific research, increased education, and a desire for alternative healthcare options.

Research and Development 105

Research and Development Marijuana History Legislation 105

Cannabis Law Report

MARCH 23, 2022

to deschedule cannabis, arguing the war on drugs has negatively affected human rights, health, security, and development on a global scale. Cannabis has been shown to be effective in the treatment of numerous medical conditions such as epilepsy, PTSD, cancer pain relief, nausea, and chronic and terminal illnesses.

Research and Development 98

Research and Development Policy Epilepsy Treatment 98

Cannabis Law Report

MAY 29, 2022

Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

MMJ Recs

OCTOBER 26, 2023

Alaska: Alaska has a robust MMJ program, allowing for the use of medical marijuana for qualifying conditions. Arizona: Arizona has a well-established MMJ program that covers various qualifying conditions, with strict possession limits. Arkansas : Arkansas has legalized MMJ for qualifying conditions.

Law 98

Law Marijuana Programs Dispensary 98

MMJ Recs

MARCH 16, 2024

With increasing acceptance of medical marijuana as a legitimate treatment option for various health conditions, the industry has attracted significant attention from investors, entrepreneurs, and policymakers alike.

Supply Chain 105

Supply Chain Research and Development Marijuana Seed-To-Sale 105

The Cannigma

MARCH 2, 2021

This issue is compounded when veterans do, on rare occasions, ask their doctors about medical marijuana, only to be treated as if they are mentally unstable or receive no specific health information at all,” the researchers found. This directly conflicts with past research claiming marijuana increases PTSD symptom severity.”.

Research and Development 143

Research and Development Treatment Chronic Pain Sleep 143

Sensi Seeds

DECEMBER 10, 2018

Much remains to be done if the progress made is to be secured, but it is clear that changes are taking place in the global debate on drug policy , especially with regard to cannabis. At the same time, research on medical cannabis over the past two decades has not ceased to increase and provide evidence of the plant’s medical value.

Medicine 81

Medicine Research and Development Data Policy 81

Cannabis Law Report

AUGUST 3, 2022

The lack of robust research on cannabis products, cannabis as a therapy and dependence or addiction to cannabis heightens the challenge of developing sound policies on the use of cannabis in health care facilities. There is very little scientific evidence for the efficacy of marijuana in treating certain medical conditions.

Research and Development 98

Research and Development Policy Patients Compliance 98

Cannabis Law Report

JULY 19, 2021

Philip Morris International recently offered £1 billion to buy Vectura Group PLC, the British pharmaceutical company that develops inhaled medical products.

Therapy 76

Therapy Data Research and Development Events 76

MMJ Recs

OCTOBER 30, 2023

Medical marijuana (MMJ) dispensaries play a crucial role in providing patients with access to the cannabis products they need for managing various health conditions. Do Ask Questions: If you’re unsure about a product or its suitability for your condition, don’t hesitate to ask the dispensary staff. Patience is key.

Dispensary 98

Dispensary Patients Strains Research and Development 98

MMJ Recs

DECEMBER 17, 2023

Enacted in 2015, the program was designed to provide a narrow avenue for patients suffering from qualifying conditions to access low-THC cannabis under the supervision of qualified healthcare professionals. Physician’s Prescription: Patients must obtain a prescription from a qualified physician registered with the TCUP.

Law 52

Law Dispensary Clinical Trials Programs 52

United Patients Group

FEBRUARY 14, 2023

Researchers administered THC to mice, then stimulated a heart attack by restricting their blood flow. After the blood flow restriction, doctors treated the mice with small amounts of THC (four times lower than the regular intoxicating dose) two hours prior to heart attack, 48 hours prior, and three weeks prior to continuous treatment.

Blood Pressure 109

Blood Pressure Sleep Research and Development Patients 109

The Cannigma

MAY 15, 2023

Ketamine has a long safety record as an anesthetic since the 1980s, and it has also been successfully used “off-label” for over a decade to treat conditions such as anxiety, depression, OCD, and PTSD, among others. Patients may want to seek assistance from a certified professional prior to embarking on treatment.

Therapy 78

Therapy Access Blood Pressure Treatment 78

Veriheal

OCTOBER 19, 2022

Warastuti, the mother of Pika Sasi Kirana, is actively lobbying for legal access and research into the plant alongside her daughter’s father, Sunarta. In 14-year-old Pika’s case, there were no obvious signs of a medical condition when she was first born. Weighing 3.4 kilograms (7.5 Nothing worked.”

Legalization 104

Legalization Research and Development Chronic Pain Treatment 104

The Cannigma

JANUARY 21, 2021

It is often called “the mother of all cannabinoids,” and it holds potential as a treatment for conditions such as diabetes, ALS, and Huntington’s disease, although human studies are seriously lacking. This is important for scientists researching the plant, but does not mean it is superior therapeutically.

Research and Development 145

Research and Development Blood Pressure Conditions Cannabinoids 145

Cannabis Law Report

JUNE 24, 2022

Scutari’s proposed “Psilocybin Behavioral Health Access and Services Act” represents a bold development in the psychedelics reform movement that’s rapidly spread in state legislatures and through citizen-led initiatives throughout the country in recent years.

Clinical Trials 52

Clinical Trials Legalization Research and Development Therapy 52

United Patients Group

FEBRUARY 8, 2023

Opioids are also prescribed to treat pain and other medical conditions such as coughs, diarrhea and muscle spasms. Natural opioids include opium or poppy seeds; synthetic ones were first developed in 1950s by German chemist Paul Janssen, who went on to found Janssen Pharmaceutica NV (now part of Johnson & Johnson).

Chronic Pain 83

Chronic Pain Cannabinoids Research and Development Patients 83

MMJ Recs

DECEMBER 22, 2023

Historically, marijuana was vilified and classified as a Schedule I controlled substance, which hindered both research and public acceptance. The AIDS epidemic in the 1980s brought attention to the potential benefits of marijuana in alleviating symptoms such as nausea and appetite loss associated with the disease and its treatment.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

MMJ Recs

MARCH 23, 2024

Legalization may offer expanded access to medical cannabis for patients suffering from various conditions, providing alternative treatment options and symptom relief. It prompts considerations regarding patient access, treatment options, and healthcare provider involvement.

Legalization 52

Legalization Access Programs Education 52

MMJ Recs

MARCH 14, 2024

Qualifying Conditions for Medical Marijuana in West Virginia West Virginia’s medical marijuana program encompasses an extensive list of qualifying conditions, providing access to patients with various chronic or debilitating diseases.

Dispensary 52

Dispensary Programs Legalization Marijuana 52

FloridaMarijuana.net

JULY 8, 2018

The National Academies of Sciences reports that PTSD is a stressor-related disorder which develops as a result of a patient’s exposure to a traumatic event. The psychological symptoms that develop because of the trauma affect mood, cognition, memories (both suppression and the inability to form new memories) and physical health.

Strains 190

Strains Indica Hybrid Research and Development 190

Cannabis Law Report

MARCH 1, 2022

The role would include being responsible for researching and analysing compliance policies and procedures, as well as developing and managing the compliance training programmes, and being responsible for legal administrative tasks. Update and establish best practices and policies.

Compliance 52

Compliance Compliance Legalization Research and Development 52

Cannabis Law Report

DECEMBER 20, 2021

Rule 154 6 of Drugs & Cosmetics Rules, 1945 states that- subject to the conditions of rule 157 being fulfilled, a licence to manufacture for sale any Ayurvedic (including Siddha) or Unani drugs shall be issued in Form 25D. Recent Development. Cannabis is a Schedule E(1) drug under the Drugs & Cosmetics Rules, 1945 9.

Seed-To-Sale 52

Seed-To-Sale Hemp Food Clinical Trials 52

MMJ Recs

MARCH 20, 2024

Many dispensaries also offer additional services such as educational resources, patient consultations, and ongoing support programs to address patient concerns and enhance their overall treatment experience. Maryland continues to embrace innovation and progress in its cannabis industry, positioning itself as a leader in the region.

Dispensary 52

Dispensary Programs Access Patients 52

Cannabis Law Report

JULY 1, 2021

On June 30th, the Petrie-Flom Center announced the launch of a three-year research initiative , the Project on Psychedelics Law and Regulation (POPLAR) , which is supported by a generous grant from the Saisei Foundation. POPLAR will publish original law and policy research.

Law 105

Law Research and Development Therapy DEA 105

United Patients Group

JUNE 26, 2023

They often possess a more profound understanding of healthcare policies, advanced practice procedures, and innovative research methodologies. These comprehensive programs focus on developing skills in patient care, policy interpretation, and research methods.

Research and Development 52

Research and Development Education Patients Policy 52

Veriheal

DECEMBER 27, 2022

Let’s dive into what the research says about these promising new findings and how they might advance the field of psychedelic research. Some research suggests that these substances could be used to treat mental health conditions like depression and anxiety. What Are Psychedelics?

Research and Development 95

Research and Development Therapy Consumption DEA 95

United Patients Group

JANUARY 11, 2023

The researchers note that this was likely due to the presence of curcumin, which has been shown to inhibit a protein called acetylcholinesterase (AChE), which is associated with Alzheimer’s disease and other types of dementia. Turmeric may also help with memory loss. May help prevent heart disease.

Research and Development 115

Research and Development Blood Pressure Treatment Conditions 115

Cannabis Law Report

AUGUST 2, 2021

42 of July 9, 2017, also known as the Act to Manage the Study, Development and Research of Cannabis for Innovation, Applicable Standards and Limits (Medicinal Cannabis Act). Therefore, its interaction with employers’ validly established drug-testing and anti-discrimination policies was a topic of public and legal debate.

Patients 98

Patients Law Research and Development Medicine 98

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

JANUARY 27, 2022

If passed the bill will establish the “Task Force on Psilocybin Equity” that will research problems relating to access and equity in Oregon’s emerging psilocybin program. The task force will complete a study and provide policy recommendations that will serve as a basis for substantive policy reforms during the 2023 legislative session.

Research and Development 52

Research and Development Policy Access Legislation 52

Cannabis Law Report

AUGUST 3, 2021

42 of July 9, 2017, also known as the Act to Manage the Study, Development and Research of Cannabis for Innovation, Applicable Standards and Limits (Medicinal Cannabis Act). Therefore, its interaction with employers’ validly established drug-testing and anti-discrimination policies was a topic of public and legal debate.

Patients 105

Patients Law Research and Development Medicine 105

United Patients Group

FEBRUARY 2, 2023

Although research into cannabis’ healing properties is still ongoing–and there are still many questions regarding dosage amounts –it seems clear that this plant can provide relief from symptoms associated with these illnesses when used properly.

Blood Pressure 104

Blood Pressure Sleep Chronic Pain Digestion 104

Cannabis Law Report

JULY 21, 2022

and previously as President and CEO of Otsuka’s North America Pharmaceutical Business, where he led the development of pharmaceutical products and digital solutions addressing complex mental health needs.

Therapy 52

Therapy Research and Development Pharmaceutical Patients 52

Cannabis Law Report

FEBRUARY 28, 2022

This innovative benefit plan is administered by Enthea, a non-profit healthcare organization responsible for medical policy development, provider network management, and benefit plan administration. The two companies believe there is significant potential for these novel treatments to heal and save lives.

Therapy 52

Therapy Treatment Research and Development Advocacy 52